/
APVO
$4.55+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.7M
1M shares
52-week range
$3.80 – $59.40
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
18.93%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-12987528.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.1M | $0 | $4.3M | $12.3M | $3.1M | $0 | $0 | $0 |
| Cost of revenue | $11.2M | $2.2M | $17.9M | $0 | $0 | $0 | $352.0K | $240.0K |
| Gross profit | $11.9M | −$2.2M | −$13.5M | $12.3M | $3.1M | $0 | −$352.0K | −$240.0K |
| Gross margin | 51.4% | — | -314.3% | 100.0% | 100.0% | — | — | — |
| R&D | $35.4M | $24.8M | $17.9M | $19.0M | $17.9M | $17.1M | $14.4M | $14.5M |
| Operating income | −$51.7M | −$41.0M | −$27.5M | −$21.4M | −$28.6M | −$28.9M | −$24.6M | −$26.3M |
| EBITDA | −$49.3M | −$40.8M | −$26.2M | −$28.3M | $7.9M | −$18.1M | −$23.8M | −$25.7M |
| Net income | −$53.7M | −$44.7M | −$17.8M | −$28.5M | $8.0M | −$17.4M | −$24.1M | −$26.0M |
| Net margin | -232.8% | — | -411.9% | -231.5% | 257.8% | — | — | — |
| EPS (diluted) | -19578811.00 | -125727793.00 | -5546028.00 | -3557646.00 | 921915.00 | -834044.00 | -31458.00 | -87.27 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-23.35 | $-24.13–$-22.57 | 1 |
| 2027 | $7M | $-12.12 | $-21.46–$-2.78 | 1 |
| 2028 | $18M | $-11.56 | $-20.76–$-2.36 | 2 |
| 2029 | $21M | $-5.35 | $-5.35–$-5.35 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5117.99
Price
$4.55
Implied upside
+112383%
Peer comparison
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
www.aptevotherapeutics.com- Employees
- 33
- IPO / List date
- Jul 20, 2016
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds APVO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in APVO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-12-30 | 1-for-18reverse |
| 2025-05-27 | 1-for-20reverse |
| 2024-12-04 | 1-for-37reverse |
| 2024-03-06 | 1-for-44reverse |
| 2020-03-27 | 1-for-14reverse |
Recent trades on TradeandTell
No one on the platform has traded APVO yet.
